Demographics, disease characteristics and clinimetry data of 68 patients included in the early spondyloarthritis clinic cohort
| Characteristic | % of patients | Clinimetry | Clinimetry data |
|---|---|---|---|
| ASQoL, ankylosing spondylitis quality of life; BASDAI, Bath Ankylosing Spondylitis Activity Index; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C reactive protein; DMARD, disease-modifying anti-rheumatic drug; ESR, erythrocyte sedimentation rate; HLA-B27, human leucocyte antigen B27; IBD, inflammatory bowel disease; IQR, interquartile range; MASES, Maastricht Ankylosing Spondylitis Enthesopathy Index; NSAID, non-steroidal anti-inflammatory drug; VAS, visual analogue scale. | |||
| *Figures are means (standard deviations) unless otherwise indicated. ‡History or presence of this symptom (% of patients). | |||
| Male | 38 | Spinal pain the past week (on a 10-cm VAS) | 4.7 (2.6)* |
| HLA-B27+ | 46 | Night pain (on a Likert scale (0–3)) | 0:18%; 1:40%; 2:38%; 3:4% |
| IBD‡ | 15 | Global well-being the past week (on a 10 cm VAS) | 3.8 (3.8) |
| Uveitis§ | 15 | Duration of morning stiffness the past week (in min; median (IQR)) | 23 (10; 60) |
| Psoriasis§ | 24 | Severity of fatigue the past week (on a 10 cm VAS) | 4.5 (2.6) |
| Family history of AS§ | 54 | 44-swollen joint count | 0.19 (0.6) |
| Dactylitis§ | 10 | Finger to floor distance (in cm; median (IQR)) | 0.0 (0–12.5) |
| Heel pain§ | 6 | Chest expansion (in cm; % of patients <4 cm) | 4.9 (2.0; 43%) |
| Peripheral arthritis§ | 28 | Lateral spinal flexion (in cm; % of patients <20 cm) | 15.2 (4.8; 90%) |
| IBP improving with NSAIDs§ | 59 | Modified Schober (in cm; % of patients <5 cm) | 15.0 (1.1; 50%) |
| Buttock pain§ | 71 | Occiput-to-wall distance (in cm; % of patients >0 cm) | 0.4 (1.7; 7%) |
| Current NSAID use | 43 | Cervical rotation (in°; % of patients <70°) | 73 (14; 32%) |
| Current DMARD use | 9 | BASDAI | 3.6 (2.1) |
| Current glucocorticoid use | 1.5 | BASFI | 2.6 (2.1) |
| Current use of IBD-related drugs | 6 | BASMI | 1.1 (1.2) |
| Criteria for inflammatory low-back pain: | MASES | 2.8(2.4) | |
| 3 Criteria present | 3 | ASQoL | 6.4 (4.8) |
| 4 Criteria present | 41 | ESR; in mm; median (IQR)) | 6 (4; 16) |
| 5 Criteria present | 56 | CRP (in mg/l; median (IQR)) | 7 (3; 9) |
| Patients with raised acute-phase reactants (in %) | 41 | ||